LifeVantage CEO Steve Fife to Retire in April
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4d ago
0mins
Should l Buy LFVN?
LifeVantage announced that after nine years at LifeVantage, Steve Fife, president, CEO and a member of the board of directors, has decided to retire in April. Fife will continue in his role as president and CEO during the transition period to ensure business continuity through his retirement date. The board is conducting an executive search and anticipates announcing the new CEO in the coming months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LFVN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LFVN
Wall Street analysts forecast LFVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LFVN is 12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 4.620
Low
12.00
Averages
12.00
High
12.00
Current: 4.620
Low
12.00
Averages
12.00
High
12.00
About LFVN
LifeVantage Corporation is an activation company, which is engage in the identification, research, development, formulation and sale of advanced nutrigenomic activators, dietary supplements, weight management products, pre- and pro-biotics, skin and hair care products, and nootropics. The Company’s line of scientifically validated activators includes the flagship Protandim family of products, TrueScience Liquid Collagen, the newest MindBody GLP-1 System, Activation-supporting nutrients such as Omega, D3+, and the Rise AM & Reset PM System , as well as AXIO nootropic energy drink mixes, the full TrueScience line of skin and hair care products, and Petandim, a pet supplement formulated to combat oxidative stress in dogs. It sells its products in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand and Singapore.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
LifeVantage Q2 2026 Earnings Call Insights
- Revenue Decline: LifeVantage reported net revenue of $48.9 million for Q2, a 27.8% year-over-year decrease primarily driven by declining sales of the MindBody GLP-1 system, highlighting intensified competition in the natural GLP-1 market that adversely affected overall performance.
- Inventory Management Strategy: The company recognized a $2.4 million reserve against a portion of its GLP-1 inventory to mitigate risks from overestimated demand, while also evaluating cost reduction opportunities to ensure sustained profitability amidst competitive pressures.
- Shareholder Return Plan: LifeVantage announced a new $60 million share repurchase authorization, reinforcing its commitment to shareholders, having returned over $20 million through dividends and share repurchases in the past six months.
- Future Outlook: The CFO provided updated guidance indicating expected revenue in the range of $185 million to $200 million, reflecting positive expectations from LoveBiome integration and the potential impact of upcoming product launches.
See More
LifeVantage (LFVN) Q2 2026 Earnings Transcript
See More
LifeVantage Q2 Earnings Report Analysis
- Earnings Performance: LifeVantage reported a Q2 non-GAAP EPS of $0.15, aligning with market expectations, yet revenue of $48.9 million fell short by $5.5 million, reflecting a significant 27.8% year-over-year decline that highlights substantial sales challenges for the company.
- Inventory Recovery: The company is working to recover from inventory stockouts, aiming to enhance future sales capabilities through improved supply chain management and inventory control, which could strengthen its competitive position in the market.
- Acquisition Impact: The acquisition of LoveBiome has affected the company's financial status; while it has not significantly boosted revenue in the short term, it may drive growth in the long term through product diversification.
- Market Reaction: Due to the revenue miss, investors are adopting a cautious stance on LifeVantage's future outlook, which may lead to stock price volatility and impact the company's performance in the capital markets.
See More
Lifevantage (LFVN) Receives Upgrade to Buy: Key Information You Need to Know
Lifevantage Upgrade: Lifevantage (LFVN) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have increased their earnings estimates for Lifevantage, with the Zacks Consensus Estimate rising by 1% over the past three months, suggesting an improvement in the company's business fundamentals.
Market Position: The upgrade places Lifevantage in the top 20% of Zacks-covered stocks, indicating its potential for near-term price appreciation due to favorable earnings estimate revisions.
See More
LifeVantage CEO to Participate in Water Tower Fireside Chat on Dec 11, 2025
- Executive Participation: LifeVantage's CEO Steve Fife and CFO Carl Aure will participate in the Water Tower Fireside Chat Series on December 11, 2025, showcasing the company's leadership in the health and wellness sector.
- Webcast Arrangement: The webcast will begin at 2:00 PM Eastern Time, allowing all investors to register and participate, aimed at enhancing interaction and transparency with stakeholders.
- Company Background: Founded in 2003 and headquartered in Lehi, Utah, LifeVantage focuses on nutrigenomics, offering a range of scientifically validated health products designed to activate optimal cellular health processes.
- Product Diversity: The company's portfolio includes the Protandim® family, TrueScience® Liquid Collagen, and other health activators, catering to diverse customer health needs and driving market growth.
See More
Align Technology Reports Strong Q4 Earnings Beat
- Earnings Beat: Align Technology reported Q4 earnings of $3.29 per share, surpassing analyst expectations of $2.97, indicating a significant improvement in profitability and boosting market confidence in future growth.
- Sales Growth: The company achieved quarterly sales of $1.047 billion, exceeding the consensus estimate of $1.033 billion, demonstrating robust performance amid strong market demand.
- Stock Surge: Align's shares jumped 10.4% in pre-market trading to $178.13, reflecting a positive investor reaction to the financial results, which may attract more investor interest.
- Increased Market Confidence: This earnings beat not only enhances Align's market image but also potentially supports its future investment and expansion plans, further solidifying its leadership position in the industry.
See More
LifeVantage Q2 2026 Earnings Call Insights
- Revenue Decline: LifeVantage reported net revenue of $48.9 million for Q2, a 27.8% year-over-year decrease primarily driven by declining sales of the MindBody GLP-1 system, highlighting intensified competition in the natural GLP-1 market that adversely affected overall performance.
- Inventory Management Strategy: The company recognized a $2.4 million reserve against a portion of its GLP-1 inventory to mitigate risks from overestimated demand, while also evaluating cost reduction opportunities to ensure sustained profitability amidst competitive pressures.
- Shareholder Return Plan: LifeVantage announced a new $60 million share repurchase authorization, reinforcing its commitment to shareholders, having returned over $20 million through dividends and share repurchases in the past six months.
- Future Outlook: The CFO provided updated guidance indicating expected revenue in the range of $185 million to $200 million, reflecting positive expectations from LoveBiome integration and the potential impact of upcoming product launches.
See More
LifeVantage (LFVN) Q2 2026 Earnings Transcript
See More
LifeVantage Q2 Earnings Report Analysis
- Earnings Performance: LifeVantage reported a Q2 non-GAAP EPS of $0.15, aligning with market expectations, yet revenue of $48.9 million fell short by $5.5 million, reflecting a significant 27.8% year-over-year decline that highlights substantial sales challenges for the company.
- Inventory Recovery: The company is working to recover from inventory stockouts, aiming to enhance future sales capabilities through improved supply chain management and inventory control, which could strengthen its competitive position in the market.
- Acquisition Impact: The acquisition of LoveBiome has affected the company's financial status; while it has not significantly boosted revenue in the short term, it may drive growth in the long term through product diversification.
- Market Reaction: Due to the revenue miss, investors are adopting a cautious stance on LifeVantage's future outlook, which may lead to stock price volatility and impact the company's performance in the capital markets.
See More
Lifevantage (LFVN) Receives Upgrade to Buy: Key Information You Need to Know
Lifevantage Upgrade: Lifevantage (LFVN) has been upgraded to a Zacks Rank #2 (Buy), indicating a positive outlook based on rising earnings estimates, which are crucial for stock price movements.
Zacks Rating System: The Zacks rating system, which evaluates stocks based on earnings estimate revisions, has a strong track record, with Zacks Rank #1 stocks averaging a +25% annual return since 1988.
Earnings Estimates: Analysts have increased their earnings estimates for Lifevantage, with the Zacks Consensus Estimate rising by 1% over the past three months, suggesting an improvement in the company's business fundamentals.
Market Position: The upgrade places Lifevantage in the top 20% of Zacks-covered stocks, indicating its potential for near-term price appreciation due to favorable earnings estimate revisions.
See More
LifeVantage CEO to Participate in Water Tower Fireside Chat on Dec 11, 2025
- Executive Participation: LifeVantage's CEO Steve Fife and CFO Carl Aure will participate in the Water Tower Fireside Chat Series on December 11, 2025, showcasing the company's leadership in the health and wellness sector.
- Webcast Arrangement: The webcast will begin at 2:00 PM Eastern Time, allowing all investors to register and participate, aimed at enhancing interaction and transparency with stakeholders.
- Company Background: Founded in 2003 and headquartered in Lehi, Utah, LifeVantage focuses on nutrigenomics, offering a range of scientifically validated health products designed to activate optimal cellular health processes.
- Product Diversity: The company's portfolio includes the Protandim® family, TrueScience® Liquid Collagen, and other health activators, catering to diverse customer health needs and driving market growth.
See More
